Drug Delivery Devices Market Scope And Analysis

Report Code : TIPHE100000854
Category : Life Sciences

Status : Published
No. of Pages : 289

Buy Now

Drug Delivery Systems Market Analysis and Scope (2019 to 2027)

Buy Now

Drug Delivery Systems Market Report Scope

Report Attribute	Details
Market size in 2018	US$ 1,243.11 Billion
Market Size by 2027	US$ 2,302.23 Billion
Global CAGR (2018 - 2027)	7.2%
Historical Data	2016-2017
Forecast period	2019-2027
Segments Covered	By Route of Administration Oral Transmucosal Injectable Topical Implantable Ocular By Distribution Channel Hospital Pharmacies Retail Pharmacies Online Pharmacies By Application Hospitals & Clinics Home Care Settings
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	BD Becton Dickinson Company Boston Scientific Corporation Novo Nordisk A S Bausch Health Companies Inc Baxter International Inc Boehringer Ingelheim Novartis AG GlaxoSmithKline plc Johnson Johnson Services Inc

Recent Developments:

Inorganic and organic strategies such as mergers and acquisitions are highly adopted by companies in the drug delivery system market. A few recent key market developments are listed below:

In June 2022, Gufic Biosciences Ltd launched a new drug delivery system, Dual Chamber Bags, at affordable prices for the first time in India. One of the most important USPs of these ready-to-use Dual Chamber Bags by Gufic is that they prevent contamination and protects the potency and efficacy of the drug. These bags also offer ease of handling at the time of reconstitution and also help in avoiding the dilution errors since the drug is present with the exact required quantity of the diluent to be used.
In February 2022, Takeda received US FDA approval for TAKHZYRO (lanadelumab-flyo) injection in a single-dose prefilled syringe (PFS), which is used to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older. The PFS is ready to use and requires fewer preparation steps than the current TAKHZYRO vial injection, while also reducing supplies and waste.